Filters
Longitudinal changes in quantitative magnetic resonance imaging metrics in children and young adults with autoimmune liver disease
Mahalingam, N., et al. (2023)
Abdominal Radiology
Read Summary ▾
Longitudinal mpMRI in paediatric/young adult autoimmune liver disease showed individual, but not group, changes in cT1, MRE, and quantitative MRCP over two years. Changes in biliary MRCP+ metrics correlated with changes in liver stiffness (MRE) and fibro-inflammation (MRE, cT1), supporting personalized trajectory tracking and noninvasive monitoring.
Multi-organ impairment and long COVID: a 1-year prospective, longitudinal cohort study
Dennis, A., et al. (2023)
Journal of the Royal Society of Medicine
Read Summary ▾
Among people recovering from acute COVID, multi-organ MRI (CoverScan) detected organ impairment in nearly 70% of patients at six months, persisting in over half at one year. Some were asymptomatic, yet impairment also tracked symptoms, especially high liver fat with severe breathlessness, supporting integration of multi-organ MRI into routine follow-up care.
Diagnosis and management of autoimmune hepatitis
Muratori, L., et al. (2023)
BMJ
Read Summary ▾
This state-of-the-art review highlights the clinical utility of cT1 in AIH diagnosis and management: it provides a quantitative, accurate, and reliable measurement of liver fibroinflammation, which correlates with histology, and predicts clinical outcomes. cT1 serves as a “virtual biopsy”, providing a “panoramic view” of liver tissue characteristics; it helps assess the heterogenous distribution of disease across the liver, supports monitoring, risk-stratification, and informs treatment-withdrawal decisions.
Quantitative imaging tests for non-alcoholic fatty liver disease: which, when and why
Dennis, A. et al. (2023)
Translational Gastroenterology and Hepatology
Read Summary ▾
This editorial reviews imaging modalities for NAFLD/NASH, endorsing PDFF for diagnosing NAFLD and positioning cT1 as the leading biomarker for NASH. It highlights cT1's utility for identifying patients with 'at-risk' NASH (with fibrosis) and for risk-stratifying patients with intermediate or indeterminate results on other guideline-recognized tests (AACE, AGA, DGVS).
Corrected T1 mapping in children and young adults with autoimmune liver disease: Correlation with histology
Trout, A. T., et al. (2023)
American Journal of Roentgenology
Read Summary ▾
Among children and young adults with autoimmune liver disease (AILD), cT1 mapping correlated strongly with histology, highlighting its ability to accurately assess liver inflammatory activity and fibrosis stage. Findings support cT1 as a useful, noninvasive tool that could reduce reliance on liver biopsy for assessing and monitoring AILD.
Multi-organ imaging demonstrates the heart-brain-liver axis in UK Biobank participants
McCracken, C., et al. (2022)
Nature Communications
Read Summary ▾
This large UK Biobank study explored the relationship between heart, brain, and liver health. Individuals with poor liver health — quantified by cT1 mapping — were more likely to have brain abnormalities (e.g., cognitive decline and dementia) and poor heart health, underscoring the importance of multi-organ assessment when assessing an individual's overall health.
NAFLD and NASH biomarker qualification in the LITMUS consortium – Lessons learned
Rasmussen, D. G. K., et al. (2022)
Journal of Hepatology
Read Summary ▾
This review distills LITMUS lessons on biomarker qualification to speed NAFLD/NASH drug development. cT1 (LiverMultiScan) was submitted to EMA/FDA for prognostic enrichment and now holds an FDA-accepted Biomarker Qualification Program, the first for a diagnostic enrichment biomarker in NASH trials, positioning cT1 to streamline recruitment and improve trial success.
Non-invasive biomarkers for liver inflammation in non-alcoholic fatty liver disease: present and future
Yip, T. C., et al. (2022)
Clinical and Molecular Hepatology
Read Summary ▾
This review highlights the importance of assessing liver inflammation in NAFLD with non-invasive biomarkers, especially in the drug development process, owing to the inaccuracies of liver biopsies. LiverMultiScan’s cT1 emerges as a robust biomarker that correlates with necroinflammation, fibrosis, and liver-related clinical outcomes, with fewer technical failures than ultrasound-based techniques.
An international survey on patterns of practice in NAFLD and expectations for therapies—The POP‐NEXT project
Ratziu, V., et al. (2022)
Hepatology
Read Summary ▾
This international survey revealed major limitations in NAFLD/NASH management: delayed referrals, suboptimal screening, and absence of reliable tools for diagnose active steatohepatitis. Most respondents used multiple noninvasive fibrosis tests but had not used cT1, underscoring unmet need; LiverMultiScan cT1 could fill this diagnostic and monitoring gap.
Artificial intelligence for precision medicine in autoimmune liver disease
Gerussi, A., et al. (2022)
Frontiers in Immunology
Read Summary ▾
This review outlines the evidence on how AI and machine learning can address unmet needs in autoimmune liver diseases. In PSC, MRCP+ metrics can significantly improve the current diagnostic approach and risk prediction. In AIH, LiverMultiScan’s cT1 is described as an accurate non-invasive biomarker for risk stratification and monitoring, enabling precision-medicine workflows.
Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH
Ratziu, V., et al. (2022)
Journal of Hepatology
Read Summary ▾
Individuals with suspected fibrotic NASH treated with FXR agonist vonafexor showed a mean 80 ms absolute reduction in cT1 at week 12 from baseline, indicating a significant reduction in liver disease activity post-treatment. These findings suggest that vonafexor is a promising therapeutic for reversing liver fibro-inflammation in NASH.
A quantitative MRCP-derived score for medium-term outcome prediction in primary sclerosing cholangitis
Cristoferi, L., et al. (2022)
Digestive and Liver Disease
Read Summary ▾
Retrospective PSC cohort: quantitative MRCP (MRCP+) stricture count and spleen length independently associated with adverse events. MRCP+ outperformed manual radiological (ANALI) scores for risk stratification in PSC, supporting use for longitudinal monitoring and as a surrogate endpoint in clinical trials.
Cardiac impairment in long COVID 1-year post-SARS-CoV-2 infection
Roca-Fernandez, A., et al. (2022)
Open Heart
Read Summary ▾
CoverScan identified cardiac abnormalities in ~20%patients at 6 months, persisting in over half of those at 12 months following initial COVID-19 symptoms. Importantly, blood biomarkers were not as sensitive as MRI in identifying cardiac abnormalities, highlighting its utility in the clinical diagnosis and management of patients with multi-system conditions.
LiverMultiScan as an alternative to liver biopsy to monitor autoimmune hepatitis in the National Health Service in England; an economic evaluation
Bajre, M., et al. (2022)
BMJ Open
Read Summary ▾
Early economic modelling from NHS England’s Oxford AHSN found LiverMultiScan to be a cost-effective, noninvasive alternative to painful, invasive surveillance liver biopsy for monitoring autoimmune hepatitis (AIH) across disease stages, saving up to £336,926, thus lowering NHS costs and procedure burden while enabling repeatable follow-up in routine care.